Telix Pharmaceuticals Limited (TLX)’s Commercial Progress Meets a Cautious Outlook

Telix Pharmaceuticals Limited (NASDAQ:TLX) is among the best NASDAQ stocks under $10 to buy. On December 15, RBC Capital assumed coverage on Telix Pharmaceuticals Limited (NASDAQ:TLX) with a Sector Perform rating and a price target of AUD17.00. The research firm notes that the company has successfully commercialized two diagnostic assets for prostate cancer and has substantial opportunities to expand indications.

Although Telix Pharmaceuticals Limited (NASDAQ:TLX) has a diverse range of pipeline assets that it’s working to commercialize, RBC expects earnings and free cash flow to remain essentially flat between fiscal years 2025 and 2027 as the company engages in R&D.

Earlier, on December 10, Telix Pharmaceuticals Limited (NASDAQ:TLX) announced a strategic clinical partnership with Varian to build applications integrating the company’s theranostic offering with external beam radiation therapy (EBRT). With an aim to accelerate radiation oncology treatments, the collaboration will initially focus on using PSMA-PET imaging for individuals undergoing prostate cancer radiotherapy.

Starting with PSMA imaging, the framework is designed to accommodate future expansion to Telix diagnostic candidates, including Zircaix and Pixclara, as well as other potential therapeutic radiopharmaceuticals. The collaboration is what the CEO and Managing Director, Dr. Christian Behrenbruch, described as “a transformative opportunity to bring precision imaging into the heart of radiation oncology.”

Overall, Telix Pharmaceuticals Limited (NASDAQ:TLX) is a consensus buy from the majority of the analysts covering the stock. The median price target of $18.14 translates to an upside potential of 110.14%.

Telix Pharmaceuticals Limited (NASDAQ:TLX) is an Australian commercial-stage biopharmaceutical company specializing in therapeutic and diagnostic radiopharmaceuticals. Founded in 2015, the company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.

While we acknowledge the potential of TLX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TLX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.